CRISPR Therap N
CRSP
USD
STOCK MARKET:
NMS
Closed
 
...
Large gap with delayed quotes
Last quote
08/30/2025 - 02:00:00
Bid
08/29/2025 - 21:59:59
Bid
Volume
Ask
08/29/2025 - 21:59:59
Ask
Volume
51.83
-1.22 ( -2.30% )
51.82
400
51.83
100
More information
Analysis by TheScreener
29.08.2025
Evaluation Slightly negative  
Interest Very weak  
Sensibility High  
Analysis date: 29.08.2025
Global Evaluation
  Slightly negative
The stock is classified in the slightly negative zone since 06.06.2025.
Interest
  Very weak
One star since 19.08.2025.
Earnings Rev Trend
  Positive
 
Compared to seven weeks ago, the analysts have raised their earnings per share estimates. This positive trend began 29.08.2025 at a price of 51.83.
Evaluation
  Strongly overvalued
 
Based on its growth potential and our own criteria, we believe the share price is currently overvalued.
MT Tech Trend
  Negative
 
The dividend-adjusted forty day technical trend is negative since 29.08.2025.
4wk Rel Perf
  -13.59%
 
The four-week dividend-adjusted underperformance versus SP500 is 13.59%.
Sensibility
  High
High, no change over 1 year.
Bear Market Factor
  High
On average, the stock has a tendency to amplify the drops in the index by 2.01%.
Bad News Factor
  Low
When the stock's pressure is specific, the market sanction on average is 3.45%.
Mkt Cap in $bn
  4.71
With a market capitalization between $2 & $8bn, CRISPR THERAPEUTICS is considered a mid-cap stock.
G/PE Ratio
  0.11
A ratio (Forecasted Growth + Estimated Dividend Yield/ Estimated Price Earnings) below 0.6 indicates that investors must pay a substantial premium for the estimated growth potential: >50% premium.
LT P/E
  -13.79
The estimated PE is negative: the financial analysts' earnings estimates forecast a loss.
LT Growth
  1.46%
The annualized growth estimate is for the current year to 2027.
Avg. Nb analysts
  23
Over the last seven weeks, an average of 23 analysts provided earnings per share estimates.
Dividend Yield
  0.00%
The company is not paying a dividend.
Beta
  160
For 1% of index variation, the stock varies on average by 1.60%.
Correlation
  0.48
48.01% of stock movements are explained by index variations.
Value at Risk
  23.24
The value at risk is estimated at USD 23.24. The risk is therefore 44.85%. This value is based on the historical volatility for a medium time period (1 month) with a confidence of 95%.
First Analysis Date
  08.09.2020